Scarica l'app Stockscreener
193.13
0.08%
-0.2697
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Precedente Chiudi:
$192.86
Aprire:
$193.3
Volume 24 ore:
65,244
Relative Volume:
0.03
Capitalizzazione di mercato:
$41.26B
Reddito:
$742.00K
Utile/perdita netta:
$-1.37B
Rapporto P/E:
-27.30
EPS:
-7.0731
Flusso di cassa netto:
$-1.07B
1 W Prestazione:
-1.64%
1M Prestazione:
-8.00%
6M Prestazione:
+99.42%
1 anno Prestazione:
+335.92%
Intervallo 1D:
$191.65
$194.39
Intervallo di 1 settimana:
$188.18
$202.02
Portata 52W:
$42.18
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Nome
Revolution Medicines Inc
Settore
Industria
Telefono
650-481-6801
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
192.49 | 41.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
516.85 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.89 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
187.12 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.96 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
364.24 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-02-27 | Ripresa | UBS | Buy |
| 2025-11-18 | Iniziato | Wolfe Research | Outperform |
| 2025-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-12 | Ripresa | Raymond James | Strong Buy |
| 2025-09-05 | Iniziato | Truist | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-08-15 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2024-07-16 | Reiterato | Needham | Buy |
| 2024-07-12 | Iniziato | Barclays | Overweight |
| 2024-07-08 | Iniziato | Jefferies | Buy |
| 2024-04-12 | Reiterato | Needham | Buy |
| 2024-04-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-04 | Iniziato | Wedbush | Outperform |
| 2023-11-16 | Iniziato | Raymond James | Outperform |
| 2023-02-28 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-10-21 | Iniziato | Oppenheimer | Outperform |
| 2022-05-20 | Iniziato | BofA Securities | Neutral |
| 2022-03-01 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-08-12 | Downgrade | Goldman | Buy → Neutral |
| 2021-05-18 | Iniziato | Goldman | Buy |
| 2020-05-21 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-09 | Iniziato | Cowen | Outperform |
| 2020-03-09 | Iniziato | Guggenheim | Buy |
| 2020-03-09 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - Yahoo Finance
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - Yahoo Finance
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today - Benzinga
Illinois grew the science behind a breakthrough cancer drug — but couldn’t hold onto the company - Crain's Chicago Business
RVMD Maintained by B of A Securities -- Price Target Raised to $265 - GuruFocus
Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space - Procopio
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 31.56% Upside in the Precision Oncology Space - DirectorsTalk Interviews
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to FTSE All-World Index - marketscreener.com
This Insider Has Just Sold Shares In Revolution Medicines - simplywall.st
Revolution Medicines chief development officer sells $67,940 in stock By Investing.com - Investing.com South Africa
Revolution Medicines Senior Advisor Executes Stock Sales via 10b5-1 Plan to Cover RSU Taxes - Kalkine Media
Revolution Medicines officer sells $353,449 in shares By Investing.com - Investing.com Nigeria
Revolution Medicines’ senior advisor sells $1.1m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CFO Jack Anders sells $807,513 in stock By Investing.com - Investing.com Australia
Revolution Medicines’ Jeff Cislini sells $670k in common stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Revolution Medicines COO Margaret Horn sells $989,612 of common stock By Investing.com - Investing.com Nigeria
Revolution Medicines CFO Jack Anders sells $807,513 in stock - Investing.com
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) exec sells 1,774 shares, keeps 39,575 RSUs - Stock Titan
Revolution Medicines (RVMD) legal chief makes pre-set stock sale for taxes - Stock Titan
Revolution Medicines (RVMD) insider adds new sale after multimillion-dollar trades - Stock Titan
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy? - The Globe and Mail
Revolution Medicines slips as investors weigh insider sale filings after recent regulatory wins - quiverquant.com
Advancing RAS(ON) Inhibition in Metastatic Pancreatic Cancer-Revolution Medicines - Oncodaily
Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift - Yahoo Finance
Revolution Medicines senior advisor Stephen Kelsey disposes of $18.7m in shares - Investing.com
Officer at Revolution Medicines (RVMD) plans 331-share sale - Stock Titan
Revolution Medicines officer plans $484K sale | RVMD SEC FilingForm 144 - Stock Titan
After $18.7M stock sale, Revolution Medicines (RVMD) officer files notice for another RSU share sale - Stock Titan
Officer at Revolution Medicines (NASDAQ: RVMD) plans 4,830-share stock sale after RSU vesting - Stock Titan
Over $16M in recent stock sales as Revolution Medicines (NASDAQ: RVMD) filer Mark A. Goldsmith plans another trade - Stock Titan
Revolution Medicines (RVMD) officer lines up another stock sale - Stock Titan
Revolution Medicines (NASDAQ: RVMD) insider plans sale of 3,939 shares - Stock Titan
Revolution Medicines’ chief commercialization officer Mancini sells $3.15m - Investing.com
Revolution Medicines to anchor former Google campus as Silicon Valley office market shifts - The Business Journals
A pancreatic cancer drug gets FDA breakthrough status. Its combo is still being tested. - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 23.28% Upside in the Biotech Sector - DirectorsTalk Interviews
Revolution Medicines (RVMD) exec exercises options, sells stock - Stock Titan
(RVMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Revolution Medicines director Lorence Kim sells $3.58m in stock By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs - Yahoo Finance
Abu Dhabi Investment Council Co P.J.S.C's Revolution Medicines Inc(RVMD) Holding History - GuruFocus
Revolution Medicines (NASDAQ: RVMD) officer plans multi-million stock option share sale - Stock Titan
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
Revolution Medicines Inc Azioni (RVMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Revolution Medicines Inc Azioni (RVMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mancini Anthony | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
1,774 |
353,449 |
42,116 |
| Kelsey Stephen Michael | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
5,569 |
1,109,554 |
286,307 |
| Horn Margaret A | Chief Operating Officer |
Sep 16 '26 |
Sale |
199.24 |
4,967 |
989,613 |
149,680 |
| GOLDSMITH MARK A | See Remarks |
Sep 16 '26 |
Sale |
199.24 |
13,988 |
2,786,938 |
253,342 |
| Cislini Jeff | SVP & General Counsel |
Sep 16 '26 |
Sale |
199.24 |
3,366 |
670,631 |
52,541 |
| Anders Jack | Chief Financial Officer |
Sep 16 '26 |
Sale |
199.24 |
4,053 |
807,513 |
119,216 |
0.99%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):